信用等级通知书 东方金诚债跟踪评字【2025】0102 号 灵康药业集团股份有限公司： 东方金诚国际信用评估有限公司根据跟踪评级安排对贵公司及"灵 康转债"的信用状况进行了跟踪评级，经信用评级委员会评定，此 次跟踪评级维持贵公司主体信用等级为 A-，评级展望为稳定，同时 维持"灵康转债"信用等级为 A-。 东方金诚国际信用评估有限公司 信评委主任 二〇二五年六月十六日 东方金诚债跟踪评字【2025】0102 号 信用评级报告声明 为正确理解和使用东方金诚国际信用评估有限公司（以下简称"东方金诚"）出具的信 用评级报告（以下简称"本报告"），本公司声明如下： 公正的关联关系，本次项目评级人员与评级对象之间亦不存在任何影响本次评级行为 独立、客观、公正的关联关系。 履行了勤勉尽责和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原 则。 级对象和第三方组织或个人的干预和影响。 真实性、准确性、完整性均由资料提供方和/或发布方负责，东方金诚按照相关性、可 靠性、及时性的原则对评级信息进行合理审慎的核查分析，但不对资料提供方和/或发 布方提供的信息合法性、真实性、准确性及完整性作任何形式的保证。 东方金诚不对 ...

2.公司药品研发是如何布局的？ 答：您好！目前重点投入的研发项目覆盖创新药、仿制药、原 料药、中药。创新药端形成多重获益的胆碱酯酶抑制剂、国内空白 证券代码：002082 证券简称：万邦德 万邦德医药控股集团股份有限公司 投资者活动记录表 编号：20250513 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关 | □媒体采访 √业绩说明会 | | 系活动类 | □新闻发布会 □路演活动 | | 别 | □现场参观 □电话会议 | | | □其他：（请文字说明其他活动内容） | | 参与单位 名称及人 | 以网络远程方式参与公司"2025年浙江辖区上市公司投资者网上 集体接待日主题活动"暨2024年度业绩说明会的投资者 | | 员姓名 | | | 时间 | 2025 年 5 月 13 日 15:00-17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 公司接待 | 董事长、总经理：赵守明 | | 人员姓名 | 董事、副总经理、董秘：刘同科 | | | 独立董事：周岳江 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 注：公司对变动较大的界定是增减额在100万元以上且增减率超过30%. 报告期内公司投资收益较上年同期增加593.87%，主要系以摊余成本计量的金融资产（应收账款及其他 应收款）终止确认为投资收益所致。 报告期内公司公允价值变动损失较上年同期增加476.71万元，主要系其他非流动金融资产在本期公允价 值产生变动所致。 报告期内资产减值损失较上年同期增加149.00%，主要系子公司康慈医疗的无形资产-商标及专利权于本 年度计提减值准备所致。 报告期内信用减值损失较上年同期减少103.81%，主要系本期计提应收款坏账准备变动所致。 资产处置收益较上年同期增加1,562.25万，主要系处置子公司康慈医疗位于江山的土地及房产所致。 报告期内营业外收入较上年同期减少676.66万元，主要系本期较去年同期营业外其他收入减少所致。 报告期内营业外支出较上年同期减少31.97%，主要系本期捐助支出减少所致。 报告期内所得税费用较上年同期增加280.19%，主要系本期应税利润总额增加所致。 四、 现金流量状况分析 单位：人民币元 ■ 注：公司对变动较大的界定是增减额在100万 ...

Core Viewpoint - The company reported a 12.66% year-on-year increase in net profit attributable to shareholders, reaching 55.44 million yuan, and achieved a positive operating cash flow of 120 million yuan in 2024, highlighting significant improvements in its financial performance [1] Financial Performance - The company's net profit attributable to shareholders increased by 12.66% year-on-year, amounting to 55.44 million yuan [1] - Operating cash flow turned positive, achieving 120 million yuan in 2024 [1] - The medical device segment significantly reduced losses by 42.49%, while the South African business turned profitable with a year-on-year net profit growth of 211.68% [1][2] Business Segments - The South African business segment achieved profitability after years of effort, marking a key highlight in the company's operational performance [2] - The company has established a strong presence in the medical device sector, with multiple orthopedic implant products certified by the FDA and CE, and a robust pipeline of new products under development [2] - The company has been focusing on the South African market for medical device distribution and maintenance services, building a stable customer base and market reputation [2][3] Innovation and R&D - The company has made significant breakthroughs in new drug development, particularly in the field of neurological drugs, with a focus on the development of the huperzine A series and methionine preparations [1][4] - As of the end of the reporting period, the company had seven new drug pipelines under research, with five of them being dual-filed in China and the U.S., indicating high-quality pipeline development [4] - The company has received FDA clinical trial approvals for WP107 and WP103, both of which are based on huperzine A, a potent cholinesterase inhibitor [4][6] Future Outlook - The company plans to enhance its international strategy by increasing the export of domestic medical devices, aiming to create a new profit contribution point [3] - The company is committed to advancing its R&D capabilities by leveraging artificial intelligence in drug development and production quality control [7] - The company aims to become a leading enterprise in the pharmaceutical and health industry through technological innovation and collaboration with academic institutions [7]